BCRX

Bioventus (BVS) reported Q3 2026 earnings of $0.17 per share, matching consensus estimates, but revenues of $142.44 million missed expectations by 4.74%. The stock has gained 79.1% year-to-date, significantly outperforming the S&P 500's 10.7% gain.

The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. BioCryst Pharmaceuticals (BCRX) is expected to report results on November 4 with anticipated earnings of $0.10 per share, representing 66.7% year-over-year growth.

BioCryst Pharmaceuticals (BCRX) has gained 4.9% over the past four weeks and currently trades at $8.52. Wall Street analysts have set a mean price target of $20.27, suggesting a potential upside of 137.9%.

The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.

BioCryst Pharmaceuticals is expected to report Q3 2026 earnings on November 4, with consensus EPS of $0.10 (up 66.7% YoY) and revenues of $166.45 million (up 4.4% YoY). However, the company has a negative Earnings ESP of -30.00% due to recent analyst estimate revisions downward, making it difficult to predict an earnings beat despite its Zacks Rank #2 rating. The company beat estimates significantly in the last quarter (+114.29% surprise).

BioCryst Pharmaceuticals announced FDA approval of ORLADEYO 150 mg oral pellets for adults and adolescents aged 12 and older with hereditary angioedema (HAE). The new pellet formulation provides an alternative to capsules for patients with difficulty swallowing or those who prefer pellet administration. ORLADEYO remains the first and only targeted oral prophylactic therapy for HAE patients aged 2 and above, with clinical data showing 91% attack-rate reduction at 96 weeks.